SICAGEN INDIA LTD. - 533014 - Closure of Trading Window
Intimation of closure of Trading Window for dealing in Company''s securities by the Designated persons and their immediate relatives from 1st July 2022 till 48 hours after the declaration of Unaudited Financial Results for the quarter ending 30th June 2022 is submitted. We request you to kindly take the above on record. SICAGEN INDIA LTD. - 533014 - Updates on Voluntary Open Offer
Saffron Capital Advisors Pvt. Ltd. ("Manager to the Offer") has submitted to BSE a copy of Corrigendum to the Detailed Public Statement (DPS) and Draft Letter of Offer (DLOO) for the attention of the public shareholders of Sicagen India Ltd ("Target Company"). SICAGEN INDIA LTD. - 533014 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Reg 24 (A) of SEBI (LODR) Regulation, 2015, Annual Secretarial Compliance Report for the FY 2021-22 issued by M/s. KRA and Associates, Practicing Company Secretaries is enclosed. SICAGEN INDIA LTD. - 533014 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
The Board of Directors, at its meeting held today, has considered and recommended the following, subject to the approval of shareholders at the ensuing 18th AGM: Re-appointment of M/s. SRSV and Associates, Chartered Accountants as the Statutory Auditors for a second term of 5 consecutive years (ie. from the conclusion of 18th AGM till the conclusion of the 23rd AGM of the Company), based on the recommendation of Audit Committee. SICAGEN INDIA LTD. - 533014 - Board Meeting Outcome for Audited Financial Results & Equity Dividend For The Year 2021-22
The Board of Directors of the Company, at its meeting held today, has inter alia considered and approved the Audited Financial Results (standalone & Consolidated) for the quarter and year ended 31st March 2022 and recommended equity dividend @ 2.5% (25 paise per share) for the year ended 31 March 2022. SICAGEN INDIA LTD. - 533014 - Corporate Action-Board approves Dividend
The Board of Directors of the Company, at its meeting held today, has recommended equity dividend @ 2.5% (25 paise per share) for the year ended 31 March 2022 and the payment of said equity dividend shall be subject to the approval of shareholders at the ensuing Annual General Meeting of the Company. SICAGEN INDIA LTD. - 533014 - Audited Financial Results For The Quarter And Year Ended 31 March 2022
The Board of Directors of the Company, at its meeting held today, has inter alia, considered and approved the Audited Financial (standalone & consolidated) Results for the quarter and year ended 31 March 2022 and recommended equity dividend @2.5% (25 paise per share) for the year ended 31 March 2022. SICAGEN INDIA LTD. - 533014 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding Loss of Share Certificates.
